KRYSTAL BIOTECH INC.

Krystal Biotech to Report Fourth Quarter and Full Year 2023 Financial Results on February 26, 2024

20 фев 2024 07:00:00 Источник Nasdaq GlobeNewswire

Krystal Biotech Receives FDA Fast Track Designation for Inhaled Oncology Candidate KB707 to Treat Solid Tumors of the Lung

13 фев 2024 07:00:00 Источник Nasdaq GlobeNewswire

Krystal Biotech Announces Publication in the New England Journal of Medicine on the Application of B-VEC to Treat Ocular Complications in Patient with Dystrophic Epidermolysis Bullosa

08 фев 2024 07:00:00 Источник Nasdaq GlobeNewswire

Krystal Biotech to Present at Guggenheim 6th Annual Biotechnology Conference

01 фев 2024 07:00:00 Источник Nasdaq GlobeNewswire

Krystal Biotech Receives Permanent J-code (J3401) for VYJUVEK®

04 янв 2024 07:00:00 Источник Nasdaq GlobeNewswire

Krystal Biotech Receives Orphan Drug Designation from the Japanese MHLW for Beremagene Geperpavec-svdt (B-VEC)

19 дек 2023 07:00:00 Источник Nasdaq GlobeNewswire

Krystal Biotech Announces EMA Validation of Marketing Authorization Application for VYJUVEK for the Treatment of Dystrophic Epidermolysis Bullosa

27 ноя 2023 07:00:00 Источник Nasdaq GlobeNewswire

Krystal Biotech to Present at the Stifel 2023 Healthcare Conference

09 ноя 2023 07:00:00 Источник Nasdaq GlobeNewswire

Krystal Biotech Announces Third Quarter 2023 Financial Results and Provides Business Update

06 ноя 2023 07:00:00 Источник Nasdaq GlobeNewswire

Krystal Biotech to Report Third Quarter 2023 Financial Results on November 6, 2023

30 окт 2023 07:00:00 Источник Nasdaq GlobeNewswire

Krystal Biotech to Present at the Chardan 7th Annual Genetic Medicines Conference

28 сен 2023 07:00:00 Источник Nasdaq GlobeNewswire

Krystal Biotech Announces FDA Clearance of Investigational New Drug Application for KB408 for the Treatment of Type 1 Alpha-1 Antitrypsin Deficiency

21 сен 2023 09:00:00 Источник Nasdaq GlobeNewswire

Krystal Biotech to Present at the Morgan Stanley 21st Annual Global Healthcare Conference

07 сен 2023 07:00:00 Источник Nasdaq GlobeNewswire

Krystal Biotech Announces Sale of Priority Review Voucher for $100 Million

21 авг 2023 07:00:00 Источник Nasdaq GlobeNewswire

Krystal Biotech Announces Second Quarter 2023 Financial Results and Operational Highlights

07 авг 2023 07:00:00 Источник Nasdaq GlobeNewswire

Krystal Biotech Announces Pipeline Expansion into Oncology and FDA Acceptance of IND Application for Lead Oncology Candidate KB707

26 июл 2023 16:14:18 Источник Nasdaq GlobeNewswire

Krystal Biotech Announces First Patient Dosed in Phase 1 Clinical Trial of KB407 for the Treatment of Cystic Fibrosis

03 июл 2023 07:00:00 Источник Nasdaq GlobeNewswire

Krystal Biotech to Present at Upcoming Investor Conferences

05 июн 2023 07:00:00 Источник Nasdaq GlobeNewswire

Krystal Biotech Announces $160 Million Private Placement Equity Financing

22 май 2023 07:00:00 Источник Nasdaq GlobeNewswire

Krystal Biotech Receives FDA Approval for the First-Ever Redosable Gene Therapy, VYJUVEK™ (beremagene geperpavec-svdt) for the Treatment of Dystrophic Epidermolysis Bullosa

19 май 2023 13:57:02 Источник Nasdaq GlobeNewswire